Cite
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
MLA
Mitsudomi, Tetsuya, et al. “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Non-Small-Cell Lung Cancer in Japanese Patients from CheckMate 816.” Cancer Science, vol. 115, no. 2, Feb. 2024, pp. 540–54. EBSCOhost, https://doi.org/10.1111/cas.16030.
APA
Mitsudomi, T., Ito, H., Okada, M., Sugawara, S., Shio, Y., Tomii, K., Okami, J., Sakakura, N., Kubota, K., Takamochi, K., Atagi, S., Tsuboi, M., Oizumi, S., Ikeda, N., Ohde, Y., Ntambwe, I., Mahmood, J., Cai, J., & Tanaka, F. (2024). Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816. Cancer Science, 115(2), 540–554. https://doi.org/10.1111/cas.16030
Chicago
Mitsudomi, Tetsuya, Hiroyuki Ito, Morihito Okada, Shunichi Sugawara, Yutaka Shio, Keisuke Tomii, Jiro Okami, et al. 2024. “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Non-Small-Cell Lung Cancer in Japanese Patients from CheckMate 816.” Cancer Science 115 (2): 540–54. doi:10.1111/cas.16030.